Skip to main content

Quest Pharmatech Inc(QPT-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.030
Day High0.030
Open:0.030
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Quest Pharmatech Inc

Select a category then submit the form to load news
GlobeNewswire
Quest PharmaTech Announces Results from AGM
AI-generated - The Globe and Mail
Quest PharmaTech: Top 25 Undervalued TSX Venture Exchange Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 25 Undervalued TSX Venture Exchange Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
GlobeNewswire
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
AI-generated - The Globe and Mail
Quest PharmaTech: Top 25 Undervalued TSX Venture Exchange Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
GlobeNewswire
Quest PharmaTech Announces Results from AGM
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Growth Stocks on TSX-V (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 25 Undervalued TSX Venture Exchange Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
Newswire.ca
Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director
AI-generated - The Globe and Mail
Quest PharmaTech: Top 25 Undervalued TSX Venture Exchange Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Growth Stocks on TSX-V (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
Newswire.ca
Quest Receives Cash Dividend Payment from OncoQuest
Newswire.ca
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
Newswire.ca
Quest PharmaTech Provides Corporate Update
Newswire.ca
Quest PharmaTech Announces Results from AGM
Newswire.ca
Quest PharmaTech Provides Product Development Update
Newswire.ca
Quest PharmaTech Provides Corporate Update

Profile

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.